Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

FDA finalizes speedier medical device pathway alternative to breakthrough status

January 6, 2021, MedTech Insight

Scott Danzis is quoted in MedTech Insight regarding the FDA’s final guidance on its new Safer Technologies Program for Medical Devices (STeP) program, which is intended to provide additional support to developers of medical devices that significantly improve on existing products. Mr. Danzis says that STeP is a "welcome complement" to the FDA's Breakthrough Devices Program. “STeP will provide an avenue for more timely interactions and collaboration with FDA reviewers for devices that provide safety improvements, but which do not qualify as breakthrough devices. I would encourage device companies to consider this pathway and discuss it with FDA early in the product development lifecycle,” he adds.

Share this article: